经皮冷冻消融与微波消融治疗肝细胞癌的安全性和肿瘤学结局比较
单中心回顾性研究纳入123例患者228个肝细胞癌病灶,比较经皮影像引导冷冻消融与微波消融的安全性和肿瘤学结局。倾向评分匹配后两组的3年局部肿瘤无进展生存率分别为57%和58%,总体及严重不良事件率亦无差异。结果显示两种消融方式用于肝细胞癌初始治疗具有相似的有利安全性和肿瘤学结局。
要点
- 冷冻消融与微波消融治疗肝细胞癌的技术成功率均为97%,局部控制效果相当。
- 两组的总体不良事件率与严重不良事件率均较低,安全性相似。
- 早期肝细胞癌初始消融后两组肝内无进展生存、肝外无进展生存和总生存无差异。
核心结论
- 经皮冷冻消融与微波消融用于肝细胞癌初始治疗显示出相似的有利安全性和肿瘤学结局。
研究设计与样本
- 单中心回顾性研究,纳入2015年12月至2023年12月接受经皮影像引导肝消融的123例患者共228个肝细胞癌病灶。
- 按手术记录不良事件,按肿瘤评估技术成功率和局部肿瘤无进展生存,倾向评分匹配后进行比较。
- 早期肝细胞癌接受初始根治性消融的患者按人统计肝内无进展生存、肝外无进展生存和总生存。
诊断标准与关键数值
- 倾向评分匹配后158个肿瘤(冷冻79个、微波79个)的技术成功率均为97%(P = .96)。
- 倾向评分匹配后3年按肿瘤计算的局部肿瘤无进展生存率冷冻消融为57%,微波消融为58%(P = .53)。
- 按手术分析170次手术(冷冻69次、微波101次),总体不良事件率冷冻消融19%、微波消融10%,严重不良事件率冷冻消融1%、微波消融3%(P = .60)。
- 早期肝细胞癌按患者分析51例(冷冻17例、微波34例),1年肝内无进展生存率冷冻82%、微波73%,肝外无进展生存率冷冻88%、微波94%,总生存率冷冻100%、微波88%(P = .76)。
临床应用与阅片要点
- 经皮冷冻消融与微波消融均为肝细胞癌初始治疗可选择的消融手段,局部控制率相当。
- 冷冻消融和微波消融的严重不良事件率均不到5%,但微波消融严重不良事件率略高。
- 1年总生存率冷冻消融为100%、微波消融为88%,提示早期肝细胞癌消融后短期生存均较佳,但组间无统计学差异。
局限性
- 单中心回顾性研究,可能存在选择偏倚。
- 冷冻消融组样本量明显小于微波消融组。
- 未报告除倾向评分匹配和Kaplan-Meier分析以外对混杂因素的全面校正细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To compare safety and oncologic outcomes of percutaneous image-guided hepatic cryoablation and microwave ablation (MWA) for treating hepatocellular carcinoma (HCC). Materials and Methods This single center, retrospective study evaluated percutaneous image-guided cryoablation and MWA procedures in patients with HCC from December 2015 to December 2023. Adverse events (AEs) were recorded per procedure. Technical success and local tumor progression-free survival were assessed per tumor and compared after propensity score matching. Intrahepatic progression-free survival, extrahepatic progression-free survival, and overall survival were measured per patient when cryoablation or MWA was used as the initial curative-intent treatment for early-stage HCC. Survival metrics were estimated using Kaplan-Meier curves and compared using log-rank testing. Results A total of 176 ablation procedures in 123 patients with 228 HCCs enabled three cohort analyses (mean age ± SD, 69 years ± 9; 85 male). Per-procedure AE analysis of 170 procedures (69 cryoablation and 101 MWA) showed no evidence of differences in overall or major AE rates (cryoablation: overall AEs, 19%, major AEs, 1%; MWA: overall AEs, 10%, major AEs, 3%; P = .60). After propensity score matching, 158 HCC tumors were studied (79 cryoablation and 79 MWA): technical success for both modalities was 97% (P = .96); 3-year per-tumor local tumor progression-free survival rates were 57% for cryoablation and 58% for MWA (P = .53). Per-patient analysis of 51 patients with early-stage HCC (17 cryoablation and 34 MWA) yielded 1-year intrahepatic progression-free survival, extrahepatic progression-free survival, and overall survival rates of 82%, 88%, and 100% for cryoablation and 73%, 94%, and 88% for MWA, respectively, without evidence of a difference in any survival outcome (P = .76). Conclusion Percutaneous cryoablation and MWA demonstrated similar favorable safety and oncologic outcomes for initial treatment of HCC. Keywords: Comparative Studies, Ablation Techniques, CT, Interventional-Oncology, Abdomen/GI, Liver © RSNA, 2026.
引用
- Chlorogiannis, Bhagavatula, Silverman, et al. Percutaneous Cryoablation Versus Microwave Ablation for Hepatocellular Carcinoma: Comparative Study of Safety and Oncologic Outcomes. Radiol Imaging Cancer. 2026. PMID: 42725882. doi:10.1148/rycan.250442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。